Form 8-K CONCERT PHARMACEUTICALS, For: Aug 12
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
Go back to Form 8-K CONCERT PHARMACEUTICALS, For: Aug 12
August 12, 2014 3:23 PM EDT
Roth Capital affirms Concert Pharmaceuticals (Nasdaq: CNCE) at Buy with a target price of $28 following the company's Q2 results.
Concert reported Q2 loss of $0.45 per share versus Roth's estimated loss of $0.47 per share.
Analyst Joseph Pantginis commented, We believe Concert is making good progress on their clinical programs, both in their in-house and partnered programs. The company's R&D expenses are... More
August 12, 2014 9:28 AM EDT
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) reported Q2 EPS of ($0.45), $0.03 worse than the analyst estimate of ($0.42). Revenue for the quarter came in at $1.2 million versus the consensus estimate of $1.3 million.
The clinical and regulatory successes we have realized in the recent months are... More
